PumpaGon (glucagon infusion pump) / LATITUDE Pharma - LARVOL DELTA

IGF-2-Mediated Hypoglycemia in a Patient with Newly Diagnosed Metastatic Sarcoma: A Rare Paraneoplastic Syndrome (ENDO 2025) - "Subsequently, chemotherapy with temozolomide and bevacizumab was initiated...Hypoglycemia is managed with supportive measures via corticosteroids, diazoxide, glucagon infusion pumps, recombinant growth hormone or dextrose fluids. IGF-2 mediated hypoglycemia is a rare paraneoplastic syndrome seen in malignancies such as sarcomas or hepatoblastomas. Hypoglycemia occurs due to overproduction of IGF-2 by the tumor which has insulin like-effects. Unlike insulin-mediated hypoglycemia, IGF-2-induced hypoglycemia occurs in the absence of insulin or C-peptide."

Clinical • Metastases • Cardiovascular • Diabetes • Hepatoblastoma • Hepatology • Hypertension • Hypoglycemia • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor • IGF1 • IGF2

Analysis of Glucose Responsive Glucagon Therapeutics using Computational Models of the Glucoregulatory System. (PubMed, Adv Healthc Mater) - "Additionally, therapeutic insulin and glucagon infusion pumps are modeled for type 1 diabetes mellitus (T1DM) human subjects to extend the results to additional datasets. These observations suggest that both the representative physiological and non-physiological models considered in this work require additional refinement to successfully describe clinical data that involve simultaneous, coupled insulin, glucose, and glucagon dynamics."

Journal • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus